* ReShape Lifesciences Inc reported a quarterly adjusted loss of 9 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $-1.56. The lone analyst forecast for the quarter was for a loss of 16 cents per share.
* Revenue fell 15% to $1.94 million from a year ago; analysts expected $2.10 million.
* ReShape Lifesciences Inc's reported EPS for the quarter was a loss of 9 cents.
* The company reported a quarterly loss of $2.19 million.
* ReShape Lifesciences Inc shares had fallen by 9.8% this quarter and lost 33.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for ReShape Lifesciences Inc is $1.00 This summary was machine generated from LSEG data May 15 at 10:27 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.16 -0.09 Beat
Dec. 31 2023 -0.18 -0.11 Beat
Sep. 30 2023 -1.20 -0.80 Beat
Jun. 30 2023 -1.79 -1.08 Beat
Comments